Therefore, we have elucidated a novel mechanism regulating RANKL- and MM-driven osteoclastogenesis, and provide evidence suggesting that FcγR targeting may represent an attractive therapeutic strategy targeting bone disease and tumor burden in MM. Here, FCGR2A is linked to Miyoshi myopathy.